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FROM THE EDITORS
Sunshine is the Best Disinfectant
Once again, Pennsylvania has made national headlines as a pioneer in the public reporting of
information related to medical quality.  Now with the release of the Pennsylvania Health Care
Cost Containment’s (PHC4) report on hospital-acquired infections (HAI) in Pennsylvania1, the
state has focused a very bright light on a critical health care issue with national policy implications.
Indeed, Pennsylvania is the first state in the nation to release a publicly funded, statewide, hospital-
specific report on the incidence of HAI.  As the longtime chairperson of the Technical Advisory
Group for PHC4, one of us (DN) has had the privilege of participating directly in this process.  
On the heels of the PHC4 report, the American Journal of Medical Quality (AJMQ) published a
series of three studies in a special supplement regarding HAI.2 These studies were highlighted in
a press conference held this past fall at the National Press Club in Washington, DC.  The three
studies, which garnered national press from USA Today3 to a cover story in Modern Healthcare4,
all noted that HAI could be prevented by changing processes of care in the hospital setting.
According to the studies, flawed hospital processes caused infection, not the severity of the
patient’s illness, contradicting long-held beliefs that the opposite was true.
In this editorial, we will review both the PHC4 report and aspects of the subsequent AJMQ
studies.  We will note how this body of work, coupled with other activities around the nation, has
led to a serious re-evaluation of the causes of HAI. Finally, we will describe the reactions of three
stakeholder groups (consumers, purchasers, and providers) to these reports.
In 2005, Pennsylvania hospitals reported a total of 19,154 cases of hospital-acquired-infections
leading to a rate of 12.2 per 1,000 cases.  The average length-of-stay (LOS) for this group was
20.6 days with an average charge of $185,260 per case.  For patients without hospital-acquired
infections, the average LOS was only 4.5 days with an average charge of $31,389 per case.  The
mortality rate for patients with a HAI was 12.9 percent compared to a mortality rate of 2.3
percent in patients without hospital-acquired-infections.  PHC4 recommends that the HAI Report
“should be used to measure individual hospital performance over time, rather than to compare
hospitals to each other.”  The report is not intended to help patients choose the “safest hospital”
rather, it is hoped that public reporting on infection rates will stimulate hospitals to assess
infection control measures and implement changes to improve performance.1
Two of the three studies published in the AJMQ Supplement examined data previously submitted
to PHC4.  The first study by Hollenbeak and colleagues5 found that despite a statistically significant
association between patient-specific factors and the patient’s risk of surgical wound infection, the
risk was largely determined by the process and practice of care.  The second study by Peng and
his team6 showed infection-related increases in mortality, LOS, and charges that could not be
explained by patient-specific factors.  The third study by Shannon7 examined data on hospital
revenues and expenses in 54 patients with central line-associated bloodstream infections (CLAB).
The average hospital cost for a patient with CLAB was $91,733, while the average reimbursement
was $65,894 resulting in a loss of $26,839 per case.  Additionally, Shannon found that process defects,
rather than age and severity of illness at the time of admission, were critical risk factors for HAI.
Of course, both publications have certain limitations.  For example, the PHC4 report includes
disparities in data-reporting by the hospitals, potential under-reporting, and the issue of risk
adjustment of the data.  The AJMQ Supplement studies were hampered by sample size and the fact
that the economic analysis was only performed on one type of HAI.  Yet, despite these limitations,
the results of both the PHC4 study and AJMQ Supplement are a one-two, knock-out punch to
previously held beliefs regarding HAI.  Specifically, HAI is not an inevitable by-product of the care
of severely ill patients being admitted to the hospital, but rather the result of flawed processes within
the delivery system and such infections have a negative impact on the hospitals’ bottom line, because
payment increases are insufficient to cover the increased marginal costs associated with HAI.2
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As for the stakeholders, from the consumers’ perspective, the
report revealed that HAI is a relatively common occurrence and
this may help the public understand the scope of the problem
and their role in its prevention. Patient advocacy groups
applauded the added transparency provided by the public
reporting of HAI.8 While research9 has questioned the lay
public’s ability to fully understand and appreciate such data,
many advocacy groups, professional organizations and
governmental agencies have developed educational programs
encouraging patients to ask the kinds of questions that might
prevent adverse occurrences. For example, the Joint Commission
has launched a “Speak Up”10 safety initiative advising patients
on how to prevent errors in care, and prevention of HAI is a
major focus of their accreditation surveys. Accumulating
evidence examining consumer attitudes about HAI and hand
hygiene concluded that not only are consumers ready to be
empowered with information to ensure a positive outcome, but
that they will also utilize infection data in selecting a health care
provider.11 A study released by Blue Cross Blue Shield12
demonstrated that out of 1,600 consumers surveyed, 77 percent
ranked quality over cost when selecting a hospital or clinic.
Other surveys confirm the public has become increasingly aware
of health care quality measures and that the number of
individuals saying they have used this information in making
decisions is increasing.13 Finally, public reporting of quality
data itself has been shown to change provider behavior in ways
that may benefit the consumers.8,14,15
From the purchasers’ perspective, the report was viewed as a
valuable tool in the efforts to improve health care quality. A
reduction of HAI is a key plank in Governor Edward Rendell’s
proposed “Prescription for Pennsylvania”.16 Health care
purchasers, increasingly sensitized to the problem, may be
tempted to include HAI rates in their performance-related fee
schedules. Many proposed pay-for-performance (P4P) systems
acknowledge the dilemma of HAI and contain provisions to
refuse payment for any medical misadventures, including HAI. 
From the providers’ perspective, the PHC4 report exposes a
difficult challenge. Ideally it will become a catalyst for positive
cultural change within the health care system, but research
confirms that behavior change is complex and that successful
measures often rely on more than a single intervention. Removal
of barriers to change, implementation of incentives, and
improved multidisciplinary communication should aid in the
process.17 In our view, the report provides compelling evidence
for the need to standardize the approach to decreasing HAI.
Therefore, we urge hospital executives to examine their
institutions’ baseline infection rate and prioritize opportunities
needed for improvement. For example, promotion of hand
hygiene, education of staff, standardization of procedures and
selective use of antibiotics carry a great cost savings potential.
As future Medicare reimbursement may be tied in part to
infection rates, a commitment to a culture of safety could
significantly impact the bottom-line of all hospitals. 
We encourage all the stakeholders to review the data in the
PHC4 report and the AJMQ Supplement, and we challenge other
states to follow Pennsylvania’s lead of tracking and reporting
hospital-acquired infections. At the AJMQ press conference in
Washington, DC PHC4’s Executive Director, Marc P. Volovka
noted, “There are still clouds on the horizon, but in Pennsylvania
the sun is shining.”  Indeed, we know that “sunshine” is the best
disinfectant. 
As always, you can reach me at David.Nash@jefferson.edu.
Bettina Berman, RN, BS
Project Director
Department of Health Policy
David Nash, MD, MBA
Editor
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It has been estimated that it takes an
average of 17 years for new knowledge to 
be integrated into clinical practice.1
The trajectory of this adoption is still
inconsistent. The rapidity of integration may
depend on the ease of changing the current
practice, the importance of integration and
other factors, such as insurance coverage (which may lag 
in some cases). The Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT) offers 
a useful case study in examining knowledge adoption.2,3
An abundance of evidence demonstrates that medications are
not only effective in treating hypertension, but also that they
considerably reduce hypertension-associated morbidity and
mortality.4 Consequently, we have seen a proliferation of new
antihypertensive agents (AAs) during the
last 20 years. Standard antihypertensive
therapies, such as diuretics (the so-called
“water pills”), have been joined by more
expensive medications, including α-
blockers, calcium channel blockers (CCBs),
angiotensin-converting enzyme (ACE)
inhibitors, and angiotensin receptor blockers (ARBs). Before
publication of (ALLHAT), little comparative data existed to help
clinicians select the most appropriate therapeutic approach for
hypertensive patients.  
Researchers at Jefferson Medical College and University 
of Utah sought to examine the effect of the ALLHAT
recommendations on physicians prescribing behavior changes.
Veteran’s Administration National Center for Patient Safety Comes to Philadelphia
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Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT): An Example for Observing Early Guideline Adoption atterns
Begun in February 1994 and completed 
in March 2002, ALLHAT is the largest
prospective hypertension trial ever conducted,
and was intended to compare effectiveness
among available AAs to provide physicians
with evidence-based recommendations. In
March 2000, the α-blocker arm of ALLHAT
was prematurely discontinued because of a
greater risk of cardiovascular events as
compared to diuretics.5 In December 2002, 
the ALLHAT findings were published,
recommending that thiazide-type diuretics
(THZD) be used for first-step therapy in uncomplicated
hypertensive patients.2 The ALLHAT results have been widely
disseminated in journal publications and even in news releases.
However, it remains to be seen whether, and to what extent,
physician prescribing behavior for AAs has changed as a result 
of the new clinical evidence. In general, evidence from clinical
trials and practice guidelines has a limited impact on physician
behavior.6
Recent trend analyses on consumption of AAs conducted 
in the United States and Canada show that physicians have, to 
some extent, responded to the new clinical evidence of ALLHAT,
prescribing significantly more diuretics and fewer ACEs, CCBs,
and α-blockers for their patients.7,8 Thus far, no information on the
impact of the ALLHAT results has been available in Europe, where
physician prescribing attitudes may be influenced substantially by
cultural factors, as well as specific pharmaceutical policies. Using a
comprehensive automated outpatient pharmacy database in Emilia
Romagna, a northern Italian Region with a population of 4 million,
we investigated trends in AA prescribing following the publication
of the ALLHAT results.9 This research has been jointly conducted
by the Center for Research in Medical Education and Health Care
and the Department of Health Policy, both at Jefferson Medical
College, supported through a collaborative agreement with the
Agenzia Sanitaria Regionale, Regione Emilia Romagna, Italy.
We examined outpatient pharmacy claims
of all Emilia Romagna residents from 2000
through 2003 and computed the monthly
total number and relative percentages of
prescriptions for THZDs, ACEs or ARBs,
CCBs, β-blockers, α-blockers, and other-
type antihypertensive diuretics.
Combinations of these antihypertensive
classes were not included in the analysis
because they accounted for small
percentages of the total number of AA
prescriptions. We performed a time series
analysis using a stepwise auto-regressive forecasting model, and
then assessed the impact of the ALLHAT recommendations o5ve
percentages and 95% confidence intervals for each of the 12
months of 2003. 
During the study period, ACEs/ARBs and CCBs represented the
largest relative percentages of AA prescriptions (approximately 40
percent and 30 percent, respectively), while the relative percentages
for other-type antihypertensive diuretics and β-blockers were
roughly 12 percent and 10 percent, respectively. Alpha-blockers
and THZDs accounted for approximately 4 percent and 1 percent
of all AA prescriptions, respectively. Use of THZDs and ACEs/
ARBs showed an overall upward trend, which was not statistically
significantly different than that predicted by the time-series model
in the 12 months, following publication of the ALLHAT findings.
The relative percentage of CCBs diminished over time, but was
significantly higher than predicted in the last 4 months of 2003.
The percentage of α-blockers was stable overall, as were the
percentages of β-blockers and other-type antihypertensive diuretics. 
This analysis provides evidence that the ALLHAT findings had
limited impact on the prescribing patterns of antihypertensive drugs
in Emilia Romagna.  Further research is needed to investigate why
Italian physicians appear unresponsive to the new clinical evidence.
Educational programs and implementation of pay-for-performance
strategies may be warranted to influence physician prescribing
behavior to improve the quality of care for hypertensive patients. 
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In a similar study, the University of Utah
Pharmacotherapy Outcomes Research Center
sought to answer the same question among
U.S. physicians using a national electronic
medical record (EMR) primary care practice
database, which contains ambulatory health
record data for over 3.2 million individuals.10
This retrospective study evaluated AA
utilization among hypertensive patients in the
year before and after publication of ALLHAT
results. Subjects for this analysis were
identified in calendar years 2002 and 2003 as
patients 18 years and older with an ICD-9
code (401.xx) for hypertension and a generic
product index (GPI) code for any of the
following 5 classes of AAs (excluding
combinations): β-blockers, ACEs, CCBs,
THZDs, and ARBs. Patients were grouped into one of five AA
classes according to the first prescription they received after
diagnosis of hypertension. 
Quartile analysis was used to compare the rates of patients on
each of the five classes of AAs for the four quarters of both 2002
and 2003.  We found a statistically significant 3.9 percent increase
in the proportion of patients on THZDs for 2003 compared to
2002. We also found a statistically significant decrease in the rate
of patients on ACEs (2.9 percent), β-blockers (1.3 percent), and
CCBs (0.5 percent), and a statistically significant increase in the
rate of patients on ARBs (0.9 percent).
Although the increase in THZD use was
modest, it supports the notion that the
ALLHAT findings had some effect on
prescribing behavior.  It remains to be seen,
however, whether such prescribing trends
would be maintained long-term.  
Conclusion
The results of these two studies show 
that the ALLHAT recommendations have
had a modest influence, if any, on physician
prescribing behaviors for AAs in two
countries. However, we also recognize that
these analyses examined data immediately
following the release of the recommendations
in late 2002; these modest changes reflect
ordering behaviors of the early adopters or integrators of the
information. While these analyses corroborate existing data in the
literature that physicians are somewhat slow, or even reluctant, to
embrace new clinical evidence, similar analyses examining
prescribing behaviors 5 or 6 years after the recommendations may
continue to show uptake and offer more insights into information
adoption. We urge that professional medical associations and
organizations worldwide begin designing, implementing, and
evaluating strategies for more effective and rapid dissemination 
of relevant results from clinical trials among their constituents. 
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The ability to maintain and update
knowledge and skills in a self-directed manner
is one of the hallmarks of the profession of
medicine.1,2 However, over recent years, the
ability of physicians to accurately self-assess
and effectively self-direct their continuing professional
development has been called into question as patient safety and
quality concerns rise to the forefront.3,4
Performance Improvement CME (PI CME) is a new vehicle
recently approved by the American Medical Association through
which CME providers can award the American Medical Association
(AMA) Physician’s Recognition Award (PRA) Category 1 Credits™.
PI CME represents a different approach to continuing professional
development, and marks a departure from traditional CME activities.
PI CME is based on a continuous cycle of improvement and calls
for a formalized approach to change and practice behavior.5 It
draws on practice-based data to assist physicians in understanding
actual performance patterns in practice, and provides the data to
guide physician self-assessment of performance. 
A PI CME activity consists of three distinct stages, each of
which is valued at five (5) AMA PRA Category 1 Credits™. Stage
A is designed to aid physicians in reviewing their performance 
in an area of practice that might benefit from closer assessment.  
In this stage, data about physician compliance with a specified
performance measure is developed from actual practice data.
Physicians are expected to review these data and make
determinations about how well they perform on the measure.
Reflection on how to address changes that may be indicated by 
the data is expected to lead to an action plan to foster change and
improvement.  Specific, measurable objectives for change and
improvement are expected.  The second stage, Stage B, consists of
participating in the planning and/or implementation of evidence-
based changes in practice using materials identified or developed
in response to the data from Stage A.  Key to this stage is the
implementation of a planned change over time.  Finally, in Stage
C, the effectiveness of the changes implemented in Stage B is
assessed, and data generated to compare against the practice-based
data from Stage A.  Participants who complete all three stages in
sequence may claim an additional five (5) credits for a total up to
20 AMA PRA Category 1 Credits™ (http://www.ama-assn.org/
ama/pub/category/15889.html).
The guided data review feature of PI CME is important 
given the reports in the literature that unguided individual self-
assessments have been found to be inaccurate when compared to
actual performance measures.3 It appears that in the world of self-
assessment, we all may be citizens of “Lake Wobegon”—
considering ourselves above average.6 In fact, as reported by
Kruger and Dunning7, not only do people tend to overestimate
their abilities when asked to self-assess, those whose actual
performances are in the bottom quartile overestimate their abilities
to a greater degree than others.  This finding has been reproduced
in a number of other studies, and it is now accepted that individual
self-assessment skills/abilities, when referenced against some
outside measure, are seldom accurate predictors of performance.
So, what does this mean for the practicing physician and the
profession of medicine?  The traditional assumption that the
physician in practice can effectively self-assess and select
appropriate continuing education activities to maintain and extend
their knowledge and skills is being questioned.2 This questions one
of the core values of a self regulating
profession.  However, new approaches are
emerging, as evidenced by the American
Board of Medical Specialties’ (ABMS)
Maintenance of Certification requirements
(http://www.abms.org/About_Board_Certification/MOC.aspx)
with their emphasis on lifelong learning, self-assessment and
practice based needs assessment.  New types of CME are being
developed that encourage performance improvement activities that
are based on individual clinical practice data. These changes are
not confined to the continuing medical education stage of the
medical education continuum;  the Accreditation Council for
Graduate Medical Education’s (ACGME) Outcomes Project
(http://www.acgme.org/outcome/) establishes practice-based
performance improvement and lifelong learning within its core
competencies for training residents, and the Liaison Committee for
Medical Education (www.lcme.org) places similar emphasis on
learning from clinical practice and establishing the habits of
lifelong learning in the medical student stage of medical education. 
Jefferson is in the forefront of developing PI CME in both
inpatient and outpatient practices.   On the inpatient side, a pilot
project gathered data from the electronic health record used by
anesthesiologists in Jefferson’s operating rooms to assess
anesthesiologists’ compliance with protocols for timely
administration of antibiotics, an important practice in reducing
surgical site infection rates.  Analysis of practice data revealed
room for improvement in compliance rates (Stage A), resulting in
the development and delivery of an educational intervention for the
participants in the pilot project (Stage B).  In early spring 2007, we
will review current compliance rates to assess the success of the PI
CME project (Stage C).  By completing the three stages in
sequence, participants will each have earned 20 AMA PRA
Category 1 Credits ™ (5 for each stage plus 5 for completing the
project), and, hopefully, improved compliance rates ultimately will
result in lower infection rates.
On the outpatient side, the Office of CME, Department of Health
Policy and Jefferson University Physicians (JUP) Clinical Care
Committee have been collaborating to pilot a PI CME activity to
examine the adequacy of chart data in the outpatient psychiatry
practice at the University. Just launched, this PI CME project is
centered on a chart audit to assess the presence of significant clinical
data in the psychiatrists’ outpatient charts.  The chart audit data
(collected by the physician) are being incorporated into a database.
Analysis will aid in the development of strategies to improve
adequacy and consistency of patient chart data across the practice.
Educational interventions will be designed and implemented, and
charts will be re-audited after six months, thus completing the three
stage model.  Through the JUP Clinical Care Committee, each clinical
group outpatient practice at the University is developing performance
improvement cycles. We expect to be able to award PI CME credit
for many of these as we refine our model and processes, and more
projects become eligible for this type of credit.  For more details 
on the Jefferson activities visit: http://jeffline.jefferson.edu/jeffcme/
office/presentations/SACMEPMSPOSTERfinal.pdf. 
Checking with ABMS specialty boards and their related
professional associations may help you locate relevant resources 
to find out more about PI CME programs available in your area.
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Despite our best efforts to safely manage all the
new drugs on the market, and the complex
therapies for the burgeoning elderly population
and chronically ill, mistakes occur each day in
every kind of health care setting. The extent of
this problem was revealed in the Institute of
Medicine’s (IOM) report To Err is Human, which
estimated that at least 7,000 patients were dying
each year from preventable medication errors.1
For 30 years, the United States Pharmacopeia
and the Institute for Safe Medication Practices (USP-ISMP)
Medication Errors Reporting Program has provided compelling
evidence of medication-use system failures through analysis of
voluntary reports. The program has alerted the health care industry to
hazardous conditions that have frequently linked ordering,
dispensing, and administration errors to ambiguous and illegible
handwritten prescriptions; look-and sound-alike drug names; and
poorly designed labeling. Despite these and other well-known
system-related issues, the majority of the public, media, regulatory
boards, and even some health care leaders continue to believe that
accountability for error prevention lies solely with front-line
practitioners, where the caregiver/patient interactions occur.
James Reason, the “grandfather” of human errors and architect of
the “Swiss cheese model” of error believed that errors are never the
result of a single failure. Instead, they represented a series of system
breakdowns, most of which are outside the control of the individual.2
The Reason model also rejects naming, blaming, and training the
practitioner closest to an error since these allows other key
stakeholders to inappropriately delegate responsibility for the error
back to that individual. A safe medication-use system requires early
identification of problems, initiation of practical safety solutions, and
universal acceptance of shared accountability among all stakeholders.3
It is paramount that health care professionals, organizations, product
vendors, academic professionals, regulatory authorities, the media,
health policy leaders, and even patients do their part to ensure a safe
medication-use system.
The IOM’s recent report, Preventing Medication Errors, outlines
the actions that stakeholders should take, including a comprehensive
examination of problems within the system and important safety
strategies and policies needed for prevention.4 Listed below are a just
a few of the essential actions for which stakeholders should be held
accountable. 
Practitioners 
Individuals must speak out about patient safety issues, voluntarily
report errors, near misses, and hazardous situations to internal and
external programs, and share personal knowledge of what went
wrong whenever an error occurs.  Further, practitioners need to
maintain competencies, stay abreast of current medication safety
literature, and make the necessary changes in practice when safety
recommendations are offered.
Health Care Leaders and Organizations
Organizations need to incorporate patient safety into their mission
statement and uphold practice issues. The affirmation that patient
safety is “Job #1” must be accompanied by genuine action and
financial commitment to a safe medication-use system. Leaders must
use clear communication techniques that allow discussions to flow
freely at all levels of the organization. Front-line practitioners must
be included in all discussions when formulating on strategies
designed to improve safety.
Organizations need to completely eliminate professional silos in
which each discipline works independently, providing episodic care
without coordination across health care providers. “Silo” thinking 
has hindered the development of a team
approach and has, thus, been at the root of many
medication errors. The inability to reconcile
medications across the continuum of health care
continues to result in patient harm and death.
External Health Care Stakeholders
Regulatory, accrediting, and licensing bodies
need to adopt safety standards as identified by
scientific research and expert committees, and
provide oversight to healthcare organizations to ensure that they are
fully implementing those safety standards. 
The pharmaceutical industry should be held accountable for
conducting pre-market testing, using proactive risk management
strategies such as failure mode and effects analysis to detect potential
labeling, packaging, or nomenclature problems. Post-marketing
surveillance is also needed to detect adverse drug reactions and
medication error-related product problems. When errors are 
reported to the manufacturer, problems should be fully disclosed to
practitioners and changes should voluntarily be made to ensure safety.
The manufacturers of medical devices and software should also be
held accountable for performing safety evaluations and for seeking
expert advice about new products. They must also freely disseminate
information to healthcare providers (and consumers, when
appropriate) when design flaws in previously launched products are
newly discovered.  
Academia
On the academic front, educators should be accountable for
weaving current medication safety concepts throughout the entire
curriculum so students can develop the critical thinking skills
necessary to manage patient safety.   
Consumers
Patients can no longer be passive about their health care. They
must see themselves as active partners and not be intimidated by
their practitioner’s disposition to ask questions about their drug
therapy. Patients should be informed that they are the last line of
defense from harm and must be proactive by providing an accurate
list of their medical history, allergies, chronic conditions, medications,
and other important medical information to their healthcare providers.
Conclusion
Since no single stakeholder can sufficiently change a system, 
all health care stakeholders must unite to prevent patient harm by
sharing accountability for providing a safe medication-use system.
As Einstein stated, “Insanity is doing the same things the same way
and expecting different results.” Thus, significant improvements 
in medication safety will not be make unless we change the way
accountability is viewed and begin to work together to finally 
design a medication-use system that is truly safe.  
HEDY COHEN, RN, BSN, MS 
VICE PRESIDENT
INSTITUTE FOR
SAFE MEDICATION PRACTICES
SENIOR SCHOLAR
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JEFFERSON MEDICAL COLLEGE
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The health gap between men and women
grows every year.  Men tend to avoid doctors,
and are much less likely than women to be
screened regularly for hypertension and
cancer.1 Prevalence of hypertension is high
among African-American men, and
adherence to treatment is problematic.
Related to uncontrolled hypertension is the
incidence of stroke.  In addition, Philadelphia’s African-
American men face disproportionately high death rates from
stroke and prostate cancer.2
The Stroke, Hypertension, and Prostate Education Intervention
Team  (SHAPE-IT) program is a unique, collaborative effort
among the Health Promotion Council of Southeastern
Pennsylvania, the Philadelphia Department of Public Health, 
the Department of Family and Community Medicine at Thomas
Jefferson University (TJU), the Division of Genetics and
Preventive Medicine of the Department of Medicine (TJU), 
and the Office to Advance Population Health (TJU Hospital).
The project is supported by a grant from the Commonwealth of
Pennsylvania.
The project’s primary goals are to educate African American
men in targeted zip codes about the risks of hypertension, stroke,
and prostate cancer, and to encourage them to visit providers for
evaluation and care.  During the course of the 3-year grant, we
expect to reach at least 25 percent (6,750 men) of the targeted
African-American male population, 35 years or older, and will
provide a more extensive assessment of the perceptions, beliefs,
and reactions from at least 900 men who have participated in the 
4-hour, interactive, educational programs led by male African-
American health educators from the Philadelphia community.
Our novel SHAPE-IT approach was developed using
collaboration with a community-based project advisory
committee, focus group sessions, and key informant interviews.
The key theme identified was the need for men to hear and learn
about their health care needs from trusted members of their
community, and have the ability to discuss their concerns in an
open, information-sharing discussion group format.
Potential project participants (African-American men) are
identified and recruited from a variety of community venues
(e.g., churches, barber shops, community centers, health fairs,
health centers).  In general, they are recruited into large group
sessions which provides a general
overview of the SHAPE-IT project is
provided.  From the larger sessions, men
are asked to participate in small group
educational sessions during which more
extensive information on prostate cancer
and the relationship between stroke and
hypertension is provided.  Pre- and post-
comparison surveys are distributed to measure the participants’
perceptions, beliefs, and reactions to the SHAPE-IT program.
We are also evaluating a group decision-making process
regarding prostate cancer screening.  Blood pressure screening 
is offered during both the large and small group sessions and
one-on-one decision-making counseling is offered to the small
group participants.  Participants’ retention of the information 
and behavioral modifications are measured with follow-up
comparison surveys administered via telephone 6 to 8 weeks
following the completion of small group sessions. 
To date, SHAPE-IT has provided information to more than
4,700 men within its target population, and has reached a subset
of 578 men in small group sessions.  The preliminary analysis
regarding pre- and post-test comparison questions shows an
increase in correct responses to knowledge-related questions. It
also shows strong program acceptance and improved likelihood
to visit providers at 2-month follow-up. 
Future administration and analysis of the follow-up survey
will provide in-depth assessments of the program’s impact and
the attitudinal and behavioral factors that may contribute to
access, adherence, and related health care issues.  This type 
of community-based intervention emphasizes community
member participation to develop enhanced patient investment
and broader systems of care.
MICHAEL P. ROSENTHAL, MD          
CLINICAL PROFESSOR AND VICE CHAIR
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In 1991, spending on home and
community-based long-term care accounted
for 14 percent of total Medicaid long-term
care expenditures. By 2005, that number had
increased to 37 percent.1 As the costs of
providing long-term care services for the
elderly and disabled continue to soar, more
and more states, and their Medicaid budgets,
are banking on a simple fact: people prefer to remain at home 
as they grow older and face the inevitable health challenges that
come with aging.  Keeping people in their homes or community-
based facilities (adult day care, assisted living facilities), instead
of institutional settings (hospitals, nursing homes) holds an
added attraction for financially stretched states.  With the
plethora of services available today, it is a strategy that can
result in better quality care, as well as being more cost-effective. 
For many years, the state- and federally-funded Medicaid
long-term care system discouraged state programs from
investing dollars in programs designed to keep elderly and
disabled beneficiaries at home rather than in long-term care
facilities.  In 1989, Arizona (AZ) elected to challenge these
restrictions by planning a program that applies managed care
principles to long-term care, i.e., giving preference to lower-cost
home and community-based services. Though faced with
roadblocks from the federal government, the Arizona Health
Care Cost Containment System (AHCCCS), the state’s Medicaid
agency, pled its case with HCFA (now the Centers for Medicare
and Medicaid Services (CMS)) and received a waiver to
implement this new long-term care model. Today, due partially
to the AZ experience, this federal barrier no longer exists. In the
nearly 20 years since the introduction of AZ’s groundbreaking
managed care model, other state Medicaid agencies have
recognized the value of supporting the elderly and disabled
populations with home and community-based care and adopted
this approach.   
Studies continue to show the cost-effectiveness of keeping
long-term care beneficiaries in a home or community
environment instead of an institution.  Nation-wide, the cost of
providing health care services to members in their own homes is
50 percent less than if the member were placed in an
institutional setting.2 In AZ, the financial returns have been
even greater. In 2005 (the most recent year for which figures are
available), the cost for maintaining a long-term care member in
an AZ institutional setting was $3,518 per month versus $1,245
for a member in a home or community setting, a cost savings of
$2,273 per member per month, or approximately 65 percent.3
AZ’s governor, Janet Napolitano, told a Congressional
committee that she will use her role as chair of the National
Governors Association to work for “meaningful reform that
includes not just the public sector, but also the engagement of
the private sector for solutions that improve the health of our
health care system.”4 AZ’s Medicaid long-term care program
provides “a robust cost-effective model for other states as they
and the federal government seek an alternative model,” Governor
Napolitano told the Senate Special Committee on Aging in July
2006.  “Expanding the AZ model to new populations could cut
Medicaid spending without eliminating services, limiting
enrollment or increasing cost sharing for the poor.”4
One thing is certain:  as states face
constant pressure to balance budgets, they
will be confronted with increasing numbers
of elderly citizens.  The nation’s elderly
population is expected to exceed 70 million
by the year 2030—twice the number in
2000, according to the American Geriatric
Society.5 Many governors and legislatures
already have announced plans to re-evaluate their Medicaid
programs in light of budget constraints and changing demographics.
At the same time, plenty of opportunities exist to improve
health outcomes and control costs for Medicaid long-term care
beneficiaries. Currently, 11 states report that less than half of
their long-term care populations are enrolled in managed care
programs, while three states—Alaska, New Hampshire and
Wyoming—have none enrolled in managed care.6 Why are
these rates still low? Because some of the same skepticism
voiced by critics of the AZ plan nearly 20 years ago persists:   
1. Managed care requires a new funding model.  Long-term
care is funded by a handful of federal and state revenue sources.
For the managed care program to work, these different funding
sources have to be coordinated. 
2. While consumers, their families, and their advocates are
critical of the existing systems, these systems are still familiar.
Change is always threatening. Even if they like the idea of a
program that allows their loved ones more flexibility in care
models, they also fear a new model might somehow fail them.     
In coming years, it will be increasingly difficult for any state
to look at its health care costs and statistics and decline to use a
managed care approach for its long-term care Medicaid programs.
As AZ’s Medicaid program for long-term care beneficiaries
shows, managed care matched with flexible care models allows
states to creatively meet the health care needs of the growing
aging population in an efficient, cost-effective manner.  
Veteran’s Administration National Center for Patient Safety Comes to Philadelphia
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Recruitment efforts for the Delaware
Valley Schweitzer Fellows Program ended
February 1, 2007. As anticipated, an
overwhelming application response was
received in the final week and a half before
the deadline. The program received 23 Fellowship applications,
with a variety of community service proposal, submitted by
medical, law, podiatry, nursing, public health, divinity, art
therapy, and public health students. All of these students have
expressed their explicit interest in community service,
“Reverence for Life,” and the exceptional life works of Albert
Schweitzer. Through a rigorous screening process, and in-person
interviews, Fellows will be selected to pursue their proposed
activities aimed at enhancing the overall health of local
communities with in the Delaware Valley. The inaugural group
of fellows will set the precedent for those to follow. 
The Department of Health Policy at
Jefferson Medical College disseminated
material about the fellowship program
throughout Delaware Valley graduate
programs to inform eligible students about
this wonderful opportunity. This approach has paid off, based on
the amount of inquiry from students, administrators, and program
directors alike. We have a diverse group of students to select
from for this inaugural class. 
We will welcome the fellows in early April 2007, and will
share more details about their projects and progress in upcoming
Health Policy newsletters.
For further information on the program, including opportunities
to sponsor a Fellow or becoming a mentor, please contact the
Program Coordinator, Nicole M. Cobb, MAOM, at 215-955-9995,
or Nicole.cobb@jefferson.edu. Also, feel free to visit our
website at www.schweitzerfellowship.org/ features/us/del. 
Veteran’s Administration National Center for Patient Safety Comes to Philadelphia
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